

Synthesis of 3,4,5-Trisubstituted Isoxazoles from Morita–Baylis–Hillman Acetates by an NaNO_2/I_2 -Mediated Domino Reaction

Shashikant U. Dighe, Sushobhan Mukhopadhyay, Shivalinga Kolle, Sanjeev Kanojiya, and Sanjay Batra*

Abstract: An efficient NaNO_2/I_2 -mediated one-pot transformation of Morita–Baylis–Hillman (MBH) acetates into alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates is described. In a cascade event, initial Michael addition of NaNO_2 to the MBH acetate furnishes the allylnitro intermediate which undergoes I_2 -catalyzed oxidative $\alpha\text{-C-H}$ nitration of the nitromethyl subunit followed by [3+2] cycloaddition to afford the title compounds. Structural elaborations of these highly substituted isoxazoles by $\text{S}_\text{N}\text{Ar}$ reactions and hydrogenolysis allows access to useful products.

Isoxazoles, a privileged class of five-member nitrogen heterocycles, occupy an important place in organic chemistry because of their wide applications in pharmaceuticals, biologically active molecules, advanced organic materials, and as intermediates in organic synthesis.^[1–5] Owing to this ubiquity, their preparation has received remarkable attention and there are already scores of elegant methods which are general, regioselective, and high yielding.^[6] As summarized by Carreira et al.,^[6m] the classical routes to isoxazole derivatives involve condensations with hydroxylamine, cyclization of ketoxime dianions, and propargylic oximes, as well as 1,3-dipolar cycloaddition reactions. Unfortunately, these methods were inefficient for the synthesis of 3-nitroisoxazoles, which are potent antimicrobials.^[7] As a consequence, a new route to 3-nitroisoxazoles by reacting tetranitromethane with electrophilic alkenes was developed.^[8] But later, based on the X-ray analysis, these products turned out to be 5-nitroisoxazoles.^[9] Therefore a general approach to substituted 3-nitroisoxazoles utilizing readily available starting materials is desired. Herein, we report a versatile route to new alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates from a reaction between Morita–Baylis–Hillman (MBH) acetates and NaNO_2 in the presence of I_2/DMSO at room temperature in short reaction

time. The process not only represents a novel cascade transformation but provides preparative access to useful 3,4,5-trisubstituted isoxazoles. Furthermore, these products are exemplified to be apposite precursors to a range of novel isoxazoles by nucleophilic aromatic substitution ($\text{S}_\text{N}\text{Ar}$) reactions and new 3,3-diamino-2-benzoylacrylates through hydrogenolysis.

The MBH adducts are advanced synthetic intermediates for several complexity generating reactions and this is manifested by their use in the construction of a plethora of heterocycles, natural products, and drug molecules.^[10] In one of our research programs focused on realizing the synthetic potential of MBH chemistry, we developed synthesis of quinolines, pyrazolo[4,3-*b*]pyridines, and thieno[3,2-*b*]pyridines by I_2 -mediated intramolecular electrophilic aromatic cyclization of primary allyl amines.^[11] Later, Yu et al. accomplished the synthesis of quinolones from allyl azides by cyclization of iminyl radicals generated by *N*-bromosuccinimide in light.^[12] These results inspired us to examine the reaction of the MBH acetate **A** with NaNO_2 and I_2 since we anticipated that a Michael reaction with **A** would afford the allyl nitro derivative **B**, which would undergo intramolecular cyclization to offer the alkyl 1-nitro-3a,7a-dihydro-1*H*-indene-2-carboxylate **E** (Scheme 1). To test the hypothesis, the MBH acetate **1ab** was treated with NaNO_2 (1.0 equiv) and iodine (1.0 equiv) at room temperature in DMF. The reaction was complete in 1 hour, thus affording a solid product in 40% yield. Unexpectedly, the structure of the product was established as methyl 3-nitro-5-(4-nitrophenyl)-


[*] S. U. Dighe,^[†] S. Mukhopadhyay,^[†] S. Kolle, S. Batra
Medicinal and Process Chemistry Division
CSIR-Central Drug Research Institute
Sector 10, Jankipuram Extension
Sitapur Road, Lucknow 226031 (India)
E-mail: batra_san@yahoo.co.uk
s_batra@cdri.res.in

Dr. S. Kanojiya
Sophisticated Analytical Instrumentation Facility, CSIR
Central Drug Research Institute (India)
Dr. S. Kanojiya, S. Batra
Academy of Scientific and Innovative Research, New Delhi (India)

[†] These authors contributed equally to this work.



Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201504529>.




Scheme 1. Initial design and unexpected results.

isoxazole-4-carboxylate (**2ab**). The formation of **2ab** can be explained on the basis of initial Michael addition of NaNO₂ and subsequent I₂-catalyzed oxidative α -C-H activation, nucleophilic addition of second nitrite ion, and [3+2] cycloaddition. Notably, nucleophilic additions by oxidative α -C-H activation in ketones, for formation of C-N and C-O bonds, is widely reported,^[13] but analogous nucleophilic addition on the C-H bond α to the nitro group is unprecedented.

It is apparent from the tentative mechanism that the reaction essentially requires 2.0 equivalents of NaNO₂ and less than a stoichiometric amount of I₂ should work. Hence we screened the reaction under different reaction conditions (see the Supporting Information). Enhancing NaNO₂ to 2.0 equivalents and reducing I₂ to 0.5 equivalents prolonged the reaction time to 6 hours but **2ab** was isolated in 92 % yield. NIS (1.0 equiv), as a I₂ source was found to be effective too, thus affording **2ab** in 90 % yield. Often the I₂-catalyzed oxidative α -C-H activation in ketones is supported by the use of terminal oxidants. Therefore we probed the reaction in the presence of 0.2 equivalents of I₂ and external oxidants including TBHP, H₂O₂, and DMSO, and it was pleasing to note that in each case the reaction was expedited and the yields of **2ab** were excellent though, DMSO proved to be superior (96 %). The CuBr₂-catalyzed nucleophilic addition to α -C-H groups of ketones by oxidative α -C-H activation has

been reported by MacMillan et al.^[13d] Likewise we too examined the reaction in the presence of CuBr₂ in DMSO and found that **2ab** was isolated in 94 % yield. Even Cu(OAc)₂ was successful under identical reaction conditions, thus affording **2ab** in 86 % yield. Nevertheless, the best reaction conditions for the transformation was reacting the MBH acetate (1.0 equiv) with NaNO₂ (2.0 equiv), I₂ (20 mol %), and DMSO (5.0 equiv) in DMF as a medium at room temperature for 3 hours.


Having optimized the reaction conditions, we turned our attention to test the scope of the protocol with various MBH acetates derived from aromatic, heteroaromatic, and aliphatic aldehydes, and the results are presented in Scheme 2. It is evident that the protocol was compatible to all MBH acetates (**1aa–aq**), generated from MBH adducts of substituted benzaldehydes and methyl acrylate, to afford the products **2aa–aq** in excellent yields. The reaction with acetates derived from heteroaldehydes revealed that thiophene, isoxazole, and pyrazole-based substrates (**1ar,1at–aw**) produced the corresponding products (**2ar,2at–aw**) in good yields but furan-based acetate **1as** only furnished methyl 3-(furan-2-yl)-2-(nitromethyl)acrylate (**3as**). Perhaps the electron-withdrawing nature of the nitro group in **3as** may lead to dearomatization of the furan ring because of its low resonance energy (see the Supporting Information). This dearomatization would



Scheme 2. Scope of the transformation of MBH acetates (**1a–c**) into isoxazoles **2**. The yield is that of the isolated product and the time to completion is provided. DMF = *N,N*-dimethylformamide, DMSO = dimethylsulfoxide.

have inhibited the α -C–H activation and concomitant attack of the nitrite ion. It may be noted that bis(isoxazole)s analogous to **2at–av** are useful in materials chemistry.^[4a] The acetate **1ax**, prepared from MBH adducts of isobutyraldehyde, also produced the isoxazole **2ax**, albeit in moderate yield. Finally varying the alkyl ester from methyl to ethyl (**1b**) or *tert*-butyl (**1c**) in the starting substrates also produced the respective 3-nitroisoxazoles (**2bb**, **2be**, **2bi**, **2by**, **2bz**, and **2cb**, **2cd**) in excellent yields.


A plausible mechanism for the formation of the isoxazoles is delineated in Scheme 3. The first step is the Michael



Scheme 3. Plausible mechanism for the transformation of MBH acetates into 3,4,5-trisubstituted isoxazoles. SET = single-electron transfer.


addition of the nitrite ion onto the MBH acetate to furnish the allylnitro derivative **G**. Molecular I_2 under the influence of DMSO is decomposed to the I_2 radical. The I_2 radical abstracts the α -hydrogen atom of **G** to form the carbon radical intermediate **H**, accompanied by liberation of one molecule of HI, which is trapped by DMSO to afford the molecular I_2 . Through additional single-electron oxidation, **H** is converted into the intermediate cation **I** which may undergo delocalization to afford the intermediate **J**. Attack of the second nitrite ion may occur either at the benzylic or allylic carbon atom, but as the allylic carbon atom is more stabilized because of the extended conjugation and *E* configuration (thermodynamically stable), it regioselectively furnishes the dinitro intermediate **K**. Rearrangement of **K** into **L** followed by a [3+2] cycloaddition reaction gives **M**, which loses water to afford 3,4,5-trisubstituted isoxazole. To gather support for the proposed mechanism during a control experiment in the presence of radical inhibitor TEMPO, we observed that the yield of **2ab** fell to 45% (Scheme 4). When reaction of **2ab** was conducted in the absence of iodine, the allylnitro derivative **3ab** was isolated in 98% yield exclusively. The reaction of **3ab** with $NaNO_2$ (1.0 equiv) and I_2 /DMSO afforded the isoxazole **2ab** in 94% yield.

To demonstrate the scalability of this protocol, the reactions of **1ab** and **1ad** were conducted on a 10 g scale, and were smoothly transformed into the isoxazole **2ab** (94%) and **2ad** (92%), respectively. Next, to demonstrate the applications of the 3-nitro-4-isoxazolecarboxylates for preparing useful isoxazole derivatives, S_NAr reactions with different nucleophiles were examined. It has been reported



Scheme 4. Control experiments. TEMPO = 2,2,6,6-tetramethylpiperidine-*N*-oxyl.

that the fluorinated isoxazoles are important for medicinal chemistry but direct electrophilic fluorination in isoxazole was inefficient.^[14] In contrast nucleophilic aromatic fluorination of heteroarenes can be realized with anhydrous TBAF under milder reaction conditions.^[15] As a result reaction of **2ab** and **2ad** with TBAF, in a THF solution, in MeCN was performed and smoothly afforded the fluorinated isoxazoles **4ab** and **4ad**, respectively, in excellent yields (Scheme 5).




Scheme 5. Utility of 3-nitroisoxazole for preparing novel isoxazole derivatives by S_NAr reactions. Boc = *tert*-butoxycarbonyl, TBAF = tetra-*n*-butylammonium fluoride, TMS = trimethylsilyl.

Likewise reaction of **2ab** with trimethylsilylcyanide in MeCN furnished the 3-cyanoisoxazole **5** in 88% yield. Furthermore nucleophilic reaction of **2ab** and **2ad** with methanol in the presence of triethylamine gave the 3-methoxyisoxazoles **6ab** and **6ad**, respectively, whereas a similar reaction with propargyl alcohol (1.1 equiv) in MeCN furnished **7ab** and **7ad**, respectively. Interestingly performing the reaction of **2ad** in the presence of 2.5 equivalents of propargyl alcohol using K_2CO_3 as the base gave **8** in 91% yield. The compounds **7ad** and **8** undergo facile click reaction with sugar azides (see the Supporting Information). The synthesis of 3-aminoisoxazoles was recently reported to be a multistep procedure

which required the formation of 3-bromoisoxazole initially.^[16] To demonstrate the utility of the title isoxazoles to access analogous compounds, we performed S_NAr reactions of **2ab** and **2ad** with secondary amines, including morpholine and *N*-Boc piperazine, which smoothly afforded the 3-aminoisoxazole derivatives **9ab,d** and **10ab,d**, respectively. Furthermore treating **2ab** and **2ad** with benzylamine gave the methyl 3-(benzylamino)-5-phenylisoxazole-4-carboxylates **11ab** and **11ad**, respectively, in excellent yields. We discovered that **1a** could be transformed into 3-aminoisoxazoles in one pot without attenuating the yield (see the Supporting Information).

Finally, given our interest in hydrogenolysis of isoxazoles,^[17,5c] we subjected **2ab**, **2ad**, and **2al** to hydrogenation in the presence of Raney-Ni using MeOH as the medium. The reaction was complete in 3 hours and afforded the novel methyl 3,3-diamino-2-benzoylacrylates **12ab**, **12ad**, and **12al**, respectively, in 89–92% yields (Scheme 6). Interestingly, the identical reaction with **2aj** resulted in formation of 3-(diaminomethylene)quinoline-2,4(1*H*,3*H*)-dione (**13**) in 83% yield.



Scheme 6. Hydrogenolysis of 3-nitro-5-aryl(isoxazole-4-carboxylates.

In summary, we have demonstrated a facile transformation of MBH acetates into alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates catalyzed by I_2 in the presence of $NaNO_2$. To the best of our knowledge, it constitutes the first example of nucleophilic addition at the C–H α to the nitro group by oxidative α -C–H activation. The reaction has been delineated to proceed by a radical mechanism. Readily available, cheap starting substrates, an inexpensive catalyst, metal-free mild reaction conditions, a simple experimental procedure, and good yields, even on larger scale, are some of the attractive attributes of the present protocol. Alternatively, the synthetic protocol is equally effective with copper(II) salts. Furthermore, we have sufficiently demonstrated that 3-nitroisoxazoles are amenable to structural modifications for accessing functionally diverse isoxazoles, 2-arylacrylates and quinoline-2,4(1*H*,3*H*)-diones. Further work concerning synthetic applications and biological assessment of these isoxazoles is underway and the results shall be reported in due course.

Acknowledgements

S.U.D. and S.M. acknowledge CSIR, New Delhi and S.K. acknowledges UGC, New Delhi for the financial support in the form of fellowships. The authors acknowledge SAIF Division of CDRI for providing the spectroscopic data, and

Prof. S. Verma, IIT Kanpur and his student B. Mohapatra for X-ray analysis. The financial assistance to S.B. from CSIR Network project HOPE (BSC 0014) to carry out this work is acknowledged. This is CDRI Communication No. 9018.

Keywords: C–H activation · cyclizations · heterocycles · iodine · Michael addition

How to cite: *Angew. Chem. Int. Ed.* **2015**, *54*, 10926–10930
Angew. Chem. **2015**, *127*, 11076–11080

- [1] a) “Isoxazoles”: D. Giomi, F. M. Cordero, F. Machetti in *Comprehensive Heterocyclic Chemistry III*, Vol. 4 (Eds.: A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, R. J. K. Taylor), Elsevier, Oxford, **2008**, pp. 365–486; b) T. M. V. D. Pinho e Melo, *Curr. Org. Chem.* **2005**, *9*, 925–958.
- [2] For pharmaceuticals: a) J. P. Waldo, R. C. Larock, *J. Org. Chem.* **2007**, *72*, 9643–9647; b) M. De Amici, C. De Micheli, G. Carrea, S. Spezia, *J. Org. Chem.* **1989**, *54*, 2646–2650.
- [3] For biological activity: a) T. Meng, D. Zhang, Z. Xie, T. Yu, S. Wu, L. Wyder, U. Regenass, K. Hilpert, M. Huang, M. Geng, J. Shen, *J. Med. Chem.* **2014**, *57*, 9832–9843; b) D. A. Hay, O. Fedorov, S. Martin, D. C. Singleton, C. Tallant, C. Wells, S. Picaud, M. Philpott, O. P. Monteiro, C. M. Rogers, S. J. Conway, T. P. C. Tumber, A. Rooney, C. Yapp, P. Filippakopoulos, M. E. Bunnage, S. Müller, S. Knapp, C. J. Schofield, P. E. Brennan, *J. Am. Chem. Soc.* **2014**, *136*, 9308–9319; c) T. H. Al-Tel, R. A. Al-Qawasmeh, R. Zaarour, *Eur. J. Med. Chem.* **2011**, *46*, 1874–1881; d) P. Ratcliffe, J. Maclean, L. Abernethy, T. Clatkinson, M. Dempster, A. M. Easson, D. Edwards, K. Everett, H. Feilden, P. Littlewood, D. McArthur, D. McGregor, H. McLuskey, O. Nimz, L. A. Nisbet, R. Palin, H. Tracey, G. Walker, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2559–2563; e) J. B. Sperry, D. L. Wright, *Curr. Opin. Drug Discov. Devel.* **2005**, *8*, 723–740.
- [4] For materials: a) P. L. van der Peet, T. U. Connell, C. Gunawan, J. M. White, P. S. Donnelly, S. J. Williams, *J. Org. Chem.* **2013**, *78*, 7298–7304; b) A. D. Burrows, C. G. Frost, M. F. Mahon, P. R. Raithby, C. Richardson, A. J. Stevenson, *Chem. Commun.* **2010**, *46*, 5064–5066; c) Y.-G. Lee, Y. Koyama, M. Yonekawa, T. Takata, *Macromolecules* **2009**, *42*, 7709–7717.
- [5] For intermediates: a) P. J. Lindsay-Scott, A. Clarke, J. Richardson, *Org. Lett.* **2015**, *17*, 476–479; b) R. C. F. Jones, A. Chatterley, R. Marty, W. M. Owtonb, M. R. J. Elsegood, *Chem. Commun.* **2015**, *51*, 1112–1115; c) P. A. Allegretti, E. M. Ferreira, *Chem. Sci.* **2013**, *4*, 1053–1058; d) B. Heasley, *Angew. Chem. Int. Ed.* **2011**, *50*, 8474–8477; *Angew. Chem.* **2011**, *123*, 8624–8627; e) V. Singh, R. Saxena, S. Batra, *J. Org. Chem.* **2005**, *70*, 353–356.
- [6] Only a few recent citations of synthesis: a) I. Nakamura, S. Gima, Y. Kudo, M. Terada, *Angew. Chem. Int. Ed.* **2015**, *54*, 7154–7157; *Angew. Chem.* **2015**, *127*, 7260–7263; b) W. Chen, J. Zhang, B. Wang, Z. Zhao, X. Wang, Y. Hu, *J. Org. Chem.* **2015**, *80*, 2413–2417; c) P. Gao, H. X. Li, X. H. Hao, D. P. Jin, D. Q. Chen, X. B. Yan, X. X. Wu, X. R. Song, X. Y. Liu, Y. M. Liang, *Org. Lett.* **2014**, *16*, 6298–6301, and references therein; d) R. Harigae, K. Moriyama, H. Togo, *J. Org. Chem.* **2014**, *79*, 2049–2058; e) M. Hu, Z. He, Z. Niu, Z. Yan, F. Zhou, Y. Shang, *Synthesis* **2014**, 510–514; f) A. Kivrak, M. Zora, *Tetrahedron* **2014**, *70*, 817–831; g) A. Sperança, B. Godoi, G. Zeni, *J. Org. Chem.* **2013**, *78*, 1630–1637; h) N. Nishiwaki, K. Kobiro, S. Hirao, J. Sawayama, K. Saigo, Y. Ise, M. Nishizawa, M. Ariga, *Org. Biomol. Chem.* **2012**, *10*, 1987–1991; i) H. Kawai, Y. Sugita, E. Tokunaga, N. Shibata, *Eur. J. Org. Chem.* **2012**, 1295–1298; j) D. Xiang, X. Xin, X. Liu, R. Zhang, J. Yang, D. Dong, *Org. Lett.* **2012**, *14*, 644–647; k) M. Ueda, S. Sugita, A. Sato, T. Miyoshi, O. Miyata, *J. Org. Chem.* **2012**, *77*, 9344–9351; l) Z.

- She, D. Niu, L. Chen, M. A. Gunawan, X. Shanja, W. H. Hersh, Y. Chen, *J. Org. Chem.* **2012**, *77*, 3627–3633; m) A. M. Jawalekar, E. Reubsaet, F. P. J. T. Rutjes, F. L. van Delft, *Chem. Commun.* **2011**, *47*, 3198–3200; n) J. A. Burkhard, B. H. Tchitchanov, E. M. Carreira, *Angew. Chem. Int. Ed.* **2011**, *50*, 5379–5382; *Angew. Chem.* **2011**, *123*, 5491–5494, and references therein; o) S. Grecian, V. V. Fokin, *Angew. Chem. Int. Ed.* **2008**, *47*, 8285–8287; *Angew. Chem.* **2008**, *120*, 8409–8411.
- [7] H. Uhr, O. Kretschik, M. Kugler, K. Wachtler, WO 2002034731, **2002** [*Chem. Abstr.* **2002**, *36*, 340670].
- [8] Y. A. Volkova, E. B. Averina, Y. K. Grishin, P. Bruheim, T. S. Kuznetsova, N. S. Zefirov, *J. Org. Chem.* **2010**, *75*, 3047–3052.
- [9] E. B. Averina, Y. V. Samoilichenko, Y. A. Volkova, Y. K. Grishin, V. B. Rybakov, A. G. Kutateladze, M. E. Elyashberg, T. S. Kuznetsova, N. S. Zefirov, *Tetrahedron Lett.* **2012**, *53*, 1472–1475.
- [10] For some reviews on utility of MBH adducts: a) S. Bhowmik, S. Batra, *Curr. Org. Chem.* **2014**, *18*, 3078–3119, and references therein; b) M. Shi, F. J. Wang, M. X. Zhao, Y. Wei, *RSC Catal. Ser.* **2011**, *0*, 0; c) D. Basavaiah, B. S. Reddy, S. S. Badsara, *Chem. Rev.* **2010**, *110*, 5447–5674; d) V. Singh, S. Batra, *Tetrahedron* **2008**, *64*, 4511–4574.
- [11] H. Batchu, S. Bhattacharyya, S. Batra, *Org. Lett.* **2012**, *14*, 6330–6333.
- [12] W.-X. Wang, Q.-Z. Zhang, T.-Q. Zhang, Z.-S. Li, W. Zhang, W. Yua, *Adv. Synth. Catal.* **2015**, *357*, 221–226.
- [13] Only a few selected citations: a) K. Yasui, T. Kato, K. Kojima, K. Nagasawa, *Chem. Commun.* **2015**, *51*, 2290–2293, and references therein for C–O and C–N bond-forming reactions: b) C. Zhu, Y. Zhang, H. Zhao, S. Huang, M. Zhang, W. Su, *Adv. Synth. Catal.* **2015**, *357*, 331–338; c) Q. Jiang, B. Xu, A. Zhao, J. Jia, T. Liu, C. Guo, *J. Org. Chem.* **2014**, *79*, 8750–8756; d) R. W. Evans, J. R. Zbieg, S. Zhu, W. Li, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2013**, *135*, 16074–16077; e) J. S. Tian, K. W. Ng, J. R. Wong, T. P. Loh, *Angew. Chem. Int. Ed.* **2012**, *51*, 9105–9109; *Angew. Chem.* **2012**, *124*, 9239–9243; f) P. Novak, R. Martin, *Curr. Org. Chem.* **2011**, *15*, 3233–3262; g) C. C. C. Johansson, T. J. Colacot, *Angew. Chem. Int. Ed.* **2010**, *49*, 676–707; *Angew. Chem.* **2010**, *122*, 686–718.
- [14] R. Palin, L. Abernethy, N. Ansari, K. Cameron, T. Clarkson, M. Dempster, D. Dunn, A.-M. Easson, D. Edwards, J. Maclean, K. Everett, H. Feilden, K.-K. Ho, S. Kultgen, P. Littlewood, D. McArthur, D. McGregor, H. McLuskey, I. Neagu, S. Neale, L.-A. Nisbet, M. Ohlmeyer, Q. Pham, P. Ratcliffe, Y. Rong, A. Roughton, M. Sammons, R. Swanson, H. Tracey, G. Walker, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 892–898.
- [15] S. J. Ryan, S. D. Schimler, D. C. Bland, M. S. Sanford, *Org. Lett.* **2015**, *17*, 1866–1869.
- [16] M. Girardin, P. G. Alsabeh, S. Lauzon, S. J. Dolman, S. G. Ouellet, G. Hughes, *Org. Lett.* **2009**, *11*, 1159–1162.
- [17] a) V. Singh, S. Madapa, G. P. Yadav, P. R. Maulik, S. Batra, *Synthesis* **2006**, 1995–2004; b) R. Saxena, V. Singh, S. Batra, *Tetrahedron* **2004**, *60*, 10311–10320.

Received: May 19, 2015

Revised: June 24, 2015

Published online: July 23, 2015